Skip Nav Destination
Issues
1 March 2013
-
Cover Image
Cover Image
The anticancer activity of green tea catechins has been known for a long time, but the mechanism of action is still unclear. The cover figure shows terminal differentiation of cancer-induced myeloid cells in the presence of the green tea catechin formulation Polyphenon E. The differentiation of immunosuppressive myeloid cells by green tea catechins promotes an antitumor T-cell response in neuroblastoma. For details, see the article by Santilli and colleagues on page 1116 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Issue Sections
Highlights
CCR Translations
CCR New Strategies
Statistics in Clinical Cancer Research
Molecular Pathways
Review
CCR Focus
Human Cancer Biology
Lack of Estrogen Receptor-α Is Associated with Epithelial–Mesenchymal Transition and PI3K Alterations in Endometrial Carcinoma
Elisabeth Wik; Maria B. Ræder; Camilla Krakstad; Jone Trovik; Even Birkeland; Erling A. Hoivik; Siv Mjos; Henrica M.J. Werner; Monica Mannelqvist; Ingunn M. Stefansson; Anne M. Oyan; Karl H. Kalland; Lars A. Akslen; Helga B. Salvesen
Cancer Therapy: Preclinical
Polyphenol E Enhances the Antitumor Immune Response in Neuroblastoma by Inactivating Myeloid Suppressor Cells
Giorgia Santilli; Izabela Piotrowska; Sandra Cantilena; Olesya Chayka; Marco D'Alicarnasso; Daniel A. Morgenstern; Nourredine Himoudi; Katie Pearson; John Anderson; Adrian J. Thrasher; Arturo Sala
GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior In Vivo Efficacy Compared with Cetuximab
Christian A. Gerdes; Valeria Gonzalez Nicolini; Sylvia Herter; Erwin van Puijenbroek; Sabine Lang; Michaela Roemmele; Ekkehard Moessner; Olivier Freytag; Thomas Friess; Carola H. Ries; Birgit Bossenmaier; Hans Joachim Mueller; Pablo Umaña
Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice
Hirohiko Kamiyama; Sherri Rauenzahn; Joong Sup Shim; Collins A. Karikari; Georg Feldmann; Li Hua; Mihoko Kamiyama; F. William Schuler; Ming-Tseh Lin; Robert M. Beaty; Balasubramanyam Karanam; Hong Liang; Michael E. Mullendore; Guanglan Mo; Manuel Hidalgo; Elizabeth Jaffee; Ralph H. Hruban; H.A. Jinnah; Richard B.S. Roden; Antonio Jimeno; Jun O. Liu; Anirban Maitra; James R. Eshleman
Inactivation or Loss of TTP Promotes Invasion in Head and Neck Cancer via Transcript Stabilization and Secretion of MMP9, MMP2, and IL-6
Elizabeth A. Van Tubergen; Rajat Banerjee; Min Liu; Robert Vander Broek; Emily Light; Shiuhyang Kuo; Stephen E. Feinberg; Amanda L. Willis; Gregory Wolf; Thomas Carey; Carol Bradford; Mark Prince; Francis P. Worden; Keith L. Kirkwood; Nisha J. D'Silva
Imaging, Diagnosis, Prognosis
Genetic Profiling Identifies Two Classes of Soft-Tissue Leiomyosarcomas with Distinct Clinical Characteristics
Antoine Italiano; Pauline Lagarde; Céline Brulard; Philippe Terrier; Marick Laë; Bernard Marques; Dominique Ranchere-Vince; Jean-Jacques Michels; Martine Trassard; Angela Cioffi; Sophie Piperno-Neumann; Christine Chevreau; Jean-Yves Blay; Corinne Delcambre; Nicolas Isambert; Nicolas Penel; Jacques-Olivier Bay; Sylvie Bonvalot; Axel Le Cesne; Jean-Michel Coindre; Frédéric Chibon
Plasma MicroRNAs as Novel Biomarkers for Endometriosis and Endometriosis-Associated Ovarian Cancer
Swati Suryawanshi; Anda M. Vlad; Hui-Min Lin; Gina Mantia-Smaldone; Robin Laskey; MinJae Lee; Yan Lin; Nicole Donnellan; Marcia Klein-Patel; Ted Lee; Suketu Mansuria; Esther Elishaev; Raluca Budiu; Robert P. Edwards; Xin Huang
Cancer Therapy: Clinical
BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
Dennie T. Frederick; Adriano Piris; Alexandria P. Cogdill; Zachary A. Cooper; Cecilia Lezcano; Cristina R. Ferrone; Devarati Mitra; Andrea Boni; Lindsay P. Newton; Chengwen Liu; Weiyi Peng; Ryan J. Sullivan; Donald P. Lawrence; F. Stephen Hodi; Willem W. Overwijk; Gregory Lizée; George F. Murphy; Patrick Hwu; Keith T. Flaherty; David E. Fisher; Jennifer A. Wargo
Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer
Colin D. Weekes; Daniel D. Von Hoff; Alex A. Adjei; Diane P. Leffingwell; S. Gail Eckhardt; Lia Gore; Karl D. Lewis; Glen J. Weiss; Ramesh K. Ramanathan; Grace K. Dy; Wen W. Ma; Beth Sheedy; Cory Iverson; Jeffrey N. Miner; Zancong Shen; Li-Tain Yeh; Ronald L. Dubowy; Michael Jeffers; Prabhu Rajagopalan; Neil J. Clendeninn
Chemoprevention of Head and Neck Cancer by Simultaneous Blocking of Epidermal Growth Factor Receptor and Cyclooxygenase-2 Signaling Pathways: Preclinical and Clinical Studies
Dong M. Shin; Hongzheng Zhang; Nabil F. Saba; Amy Y. Chen; Sreenivas Nannapaneni; A.R.M. Ruhul Amin; Susan Müller; Melinda Lewis; Gabriel Sica; Scott Kono; Johann C. Brandes; William J. Grist; Rachel Moreno-Williams; Jonathan J. Beitler; Sufi M. Thomas; Zhengjia Chen; Hyung Ju C. Shin; Jennifer R. Grandis; Fadlo R. Khuri; Zhuo Georgia Chen
Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma
Eric Angevin; Jose A. Lopez-Martin; Chia-Chi Lin; Jürgen E. Gschwend; Andrea Harzstark; Daniel Castellano; Jean-Charles Soria; Paramita Sen; Julie Chang; Michael Shi; Andrea Kay; Bernard Escudier
Predictive Biomarkers and Personalized Medicine
Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial
Bryan P. Schneider; Robert J. Gray; Milan Radovich; Fei Shen; Gail Vance; Lang Li; Guanglong Jiang; Kathy D. Miller; Julie R. Gralow; Maura N. Dickler; Melody A. Cobleigh; Edith A. Perez; Tamara N. Shenkier; Kirsten Vang Nielsen; Sven Müller; Ann Thor; George W. Sledge, Jr; Joseph A. Sparano; Nancy E. Davidson; Sunil S. Badve
Letters to the Editor
Correction
Advertisement
